Advertisement
Screener

KODIAK SCIENCES INC. (KOD) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Kodiak Sciences Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Kodiak Sciences Inc. return tang equity for the quarter ending 2026-06-30 was -396.09%, a change of -111.80% year-over-year.
  • Kodiak Sciences Inc. return tang equity for the quarter ending 2026-03-31 was -205.76%, a change of -30.62% year-over-year.
  • Kodiak Sciences Inc. return tang equity for the quarter ending 2025-12-31 was -146.12%, a change of -28.87% year-over-year.
  • Kodiak Sciences Inc. return tang equity for the quarter ending 2025-09-30 was -917.34%, a change of -813.97% year-over-year.
  • Kodiak Sciences Inc. return tang equity for fiscal 2025 was -146.12%, a change of -28.87% from fiscal 2024.
  • Kodiak Sciences Inc. return tang equity for fiscal 2024 was -117.25%, a change of -19.24% from fiscal 2023.
  • Kodiak Sciences Inc. return tang equity for fiscal 2023 was -98.01%, a change of -21.47% from fiscal 2022.
  • Kodiak Sciences Inc. return tang equity for fiscal 2022 was -76.54%, a change of -36.29% from fiscal 2021.
Available history
2016-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-396.09%-$241.99M$61.1M
2026-03-31-205.76%-$230.66M$112.1M
2025-12-31-146.12%-$229.97M$157.38M
2025-09-30-917.34%-$217.34M$23.69M
2025-06-30-284.29%-$199.83M$70.29M
2025-03-31-175.14%-$190.63M$108.84M
2024-12-31-117.25%-$176.21M$150.29M
2024-09-30-103.37%-$191.62M$185.37M
2024-06-30-92.16%-$197.68M$214.51M
2024-03-31-96.50%-$232.75M$241.19M
2023-12-31-98.01%-$260.49M$265.78M
2023-09-30-89.75%-$271.42M$302.42M
2023-06-30-88.18%-$298.45M$338.48M
2023-03-31-78.68%-$308.89M$392.59M
2022-12-31-76.54%-$333.82M$436.17M
2022-09-30-74.35%-$356.54M$479.53M
2022-06-30-65.36%-$347.03M$530.93M
2022-03-31-52.27%-$312.25M$597.38M
2021-12-31-40.25%-$266.99M$663.32M
2021-09-30-30.35%-$220.41M$726.32M
2021-06-30-24.25%-$189M$779.43M
2021-03-31-19.37%-$159.15M$821.68M
2020-12-31-15.46%-$133.1M$860.75M
2020-09-30-36.24%-$102.13M$281.78M
2020-06-30-25.35%-$78.39M$309.2M
2020-03-31-19.46%-$63.77M$327.69M
2019-12-31-13.71%-$47.37M$345.36M
2019-09-30-77.75%-$46.41M$59.69M
2019-06-30-63.53%-$44.48M$70.02M
2019-03-31-50.57%-$40.51M$80.1M
2018-12-31-47.73%-$41.44M$86.83M
2018-09-3058.30%-$54.7M-$93.83M
2018-06-3052.54%-$44.25M-$84.23M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-146.12%-$229.97M$157.38M
2024-12-31-117.25%-$176.21M$150.29M
2023-12-31-98.01%-$260.49M$265.78M
2022-12-31-76.54%-$333.82M$436.17M
2021-12-31-40.25%-$266.99M$663.32M
2020-12-31-15.46%-$133.1M$860.75M
2019-12-31-13.71%-$47.37M$345.36M
2018-12-31-47.73%-$41.44M$86.83M
2017-12-3140.64%-$27.94M-$68.74M
2016-12-3141.70%-$17.13M-$41.08M

Similar stocks

Stock NameCountryMarket CapPE Ratio
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Vericel Corp (VCEL)United States$2.011B93.97
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
Greenland Mines Ltd (GRML)United States$2.362B
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Immunocore Holdings plc (IMCR)$1.613B-90.43